Dean, Emma

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., et al. (2019) · The Lancet Oncology

Monoclonal and Polyclonal Antibodies ResearchLung Cancer Treatments and Mutations

Cited by 237

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

Cortes, J., Tamura, K., DeAngelo, D. J., de Bono, J., Lorente, D., Minden, M., Uy, G. L., Kantarjian, H., Chen, L. S., Gandhi, V., et al. (2018) · British Journal of Cancer

Acute Myeloid Leukemia ResearchCancer Mechanisms and Therapy

Cited by 120

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 21